Craft
NovoCure

NovoCure

Phase III Trials Products

3

FY, 2021

Revenue

$535 M

FY, 2021

Market Capitalization

$8.1 B

2022-09-30

NovoCure Summary

Company summary

Overview
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. It markets its proprietary therapy, Tumor Treating Fields (TTFields), that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die. The TTFields therapy is used as a monotherapy treatment for adult patients with glioblastoma brain cancer and malignant pleural mesothelioma. The company is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer.
Type
Public
Founded
2000
HQ
Saint Helier, JE | view all locations
Website
https://www.novocure.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Asaf Danziger

    Asaf Danziger, Chief Executive Officer, Director

  • Wilco Groenhuysen

    Wilco Groenhuysen, Chief Operating Officer

  • Ashley Cordova

    Ashley Cordova, Chief Financial Officer

  • Pritesh Shah

    Pritesh Shah, Chief Commercial Officer

Operating MetricsView all

Patents and Patent Applications

185
2.8%

FY, 2020

Phase III Trials Products

3
40.0%

FY, 2021

Phase II Trials Products

6
100.0%

FY, 2021

LocationsView all

8 locations detected

  • Saint Helier, St Helier HQ

    Jersey

    No.4 The Forum, Grenville Street

  • Malvern, PA

    United States

    20 Valley Stream Pkwy # 300

  • New York, NY

    United States

    1500 Broadway, 17th Floor

  • Portsmouth, NH

    United States

    195 Commerce Way

  • München, BY

    Germany

    Elektrastraße 6

  • Haifa, Haifa District

    Israel

    Topaz Building 4th Floor MATAM Center

and 2 others

NovoCure Financials

Summary financials

Revenue (Q2, 2022)
$140.9M
Gross profit (Q2, 2022)
$114.9M
Net income (Q2, 2022)
($24.0M)
Cash (Q2, 2022)
$367.0M
EBIT (Q2, 2022)
($20.2M)
Enterprise value
$8.4B

Footer menu